Eletriptan: pharmacological differences and clinical results
by
Giffin N.
National Hospital, Queen Square, London, UK.
n.giffin@ion.ucl.ac.uk
Curr Med Res Opin 2001;17 Suppl 1:s59-62

ABSTRACT

The potential advantages of eletriptan lie firstly in its lipophilicity reflected as an increased rate of absorption and Tmax compared to sumatriptan. This is manifested in a modest advantage over sumatriptan in terms of speed of onset, 2 h headache response and 2 h pain free. However, eletriptan has not yet been shown to have an advantage over the other triptans for lack of head-to head comparisons. It does not appear to have an advantage over sumatriptan for headache recurrence. The second advantage is the partial agonist activity at the 5-HT(1B) receptor, reducing the potential for cardiovascular side-effects compared to the other triptans. Although no serious cardiovascular events have yet been recognized, eletriptan should still be used with extreme caution for patients with cardiovascular risk factors.

Triptans
Migraine
Sumatriptan
Zolmitriptan
Moclobemide
Beta-blockers
Antidepressants
Migraine prophylaxis
Venlafaxine/headaches
Eleptriptan (Relpax): review
Sumatriptan (Imitrex, Imigran)
Triptans, migraine and depression
Eleptriptan (Relpax) v sumatriptan

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family